key: cord-0746389-a0gg2upx
authors: Suwanwongse, K.; Shabarek, N.
title: Epidemiology, clinical features, and outcomes of hospitalized infants with COVID-19 in the Bronx, New York
date: 2020-08-06
journal: Arch Pediatr
DOI: 10.1016/j.arcped.2020.07.009
sha: 5acdcd687f68684e1497c2be76c8624ad44e41b0
doc_id: 746389
cord_uid: a0gg2upx

nan

60%). One infant presented with a cough (20%). None had diarrhea or vomiting. The median duration from symptom onset to admission was 3 days (range: 1-3 days).

Three (60%) infants had neutropenia with lymphocytosis. None had lymphopenia or thrombocytopenia. Procalcitonin levels were mildly elevated (range: 0.09-0.2 ng/mL) in four (80%) infants and were normal in one (20%) infant. Four (80%) infants had abnormal chest X-ray findings consistent with viral pneumonia, while one (20%) infant had a normal chest X-ray. For all infants, the blood culture, influenza, and respiratory syncytial virus test results were negative.

None required supplemental oxygen nor invasive mechanical ventilation. None of the infants had acute kidney injury or shock. The median length of hospital stay was 5 days (range: 2-11 days). All infants received symptomatic treatment without specific antiviral medications. One infant received steroids for 5 days for possible acute bronchiolitis.

The clinical features and outcomes of infants with COVID-19 in our case series are different from those reported for adults [2, 3] . Isolated fever and nasal congestion were common presentations.

Obesity was also frequent in infants with COVID-19 but it did not seem to be associated with disease severity. Passive smoking and breastfeeding might not be related to the risk of developing COVID-19 nor impact its clinical course. All of the infants in our report had favorable prognoses and were discharged home safely.

Our study revealed a benign course of COVID-19 in infants, similar to previously published reports [4, 5] . The reasons why infants have better prognoses than those of adults remain unknown. We proposed two possible mechanisms underlying the more favorable courses of COVID-19 in infants:

(1) low expression of angiotensin-converting enzyme (ACE2) receptors in infant lungs; (2) immaturity of the infant immune system.

SARS-CoV-2 binds to ACE2 receptors to enter human cells [6] . ACE2 receptors are predominately expressed by type 2 pneumocytes in the lungs explaining why pneumonia is the most prevalent clinical manifestation of COVID-19 [6] . The infant's lungs are not fully developed, with incomplete expression of ACE2 receptors and their underlying pathway. Thus, SARS-CoV-2 may have lower infectivity and virulence in infants than in adults due to the limited entry and functional pathway.

Interestingly, infants with COVID-19 tend to have neutropenia with lymphocytosis. This may be explained by the immaturity of the infant immune system with possibly fewer cytokine responses.

The deficit in B-cell function is characteristic of the immature immune development in babies, especially those younger than 6 months. We recently hypothesized that preexisting B-cell suppression has a positive impact on prognosis of COVID-19 [7] . Therefore, favorable COVID-19 outcomes in infants may at least partly be due to their underdeveloped B-cell function.

In conclusion, the clinical course of COVID-19 in infants from our case series seemed more favorable than in adults. However, due to the small number of infants, further research is needed to verify our observation and investigate the underlying causes. Although the clinical outcome of COVID-19 in infants tends to be non-lethal, clinicians should be aware that infants also may develop lifethreatening COVID-19 pneumonia and septic shock as occurs in adults. Therefore, proper supportive intensive care measures should be implemented prompt when indicated. Another concerning issue, which is understudied, is whether SARS-CoV-2 can cause permanent long-term sequelae in infected infants.

WHO Coronavirus disease

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China

COVID-19 in Neonates and Infants: Progression and Recovery

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab